Summary
46.35 -0.30(-0.64%)06/27/2025
Bristol-Myers Squibb Company (BMY)
BMY reported last earnings on 2025-04-24 after the market. An EPS of $1.8 was observed compared to an estimated EPS of $1.49, resulting in a surprise value of $0.31. A revenue of $11,201 million was observed compared to an estimated revenue of $10,695 million, resulting in a surprise value of $506 Million.
Bristol-Myers Squibb Company (BMY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 0.03 | -1.21 | -1.15 | -20.46 | -17.88 | 17.13 | -5.35 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Fundamental Ratings
| Category | Rating |
| Main Rating | B+ |
| Recommended Rating | Neutral |
| DCF | Strong Buy |
| ROE | Strong Buy |
| ROA | Strong Buy |
| Debt/Equity | Strong Sell |
| P/E | Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 46.37 | |
| Open | 46.41 | |
| High | 46.73 | |
| Low | 46.17 | |
| Volume | 9,279,241 | |
| Change | 0.02 | |
| Change % | 0.03 | |
| Avg Volume (20 Days) | 14,213,164 | |
| Volume/Avg Volume (20 Days) Ratio | 0.65 | |
| 52 Week Range | 38.36 - 62.65 | |
| Price vs 52 Week High | -25.99% | |
| Price vs 52 Week Low | 20.86% | |
| Range | 0.00 | |
| Gap Up/Down | -0.24 | |
Profitibility | ||
| Market Capitalization (Mln) | 98,325 | |
| Revenue per share | 23.4545 | |
| Net Income per share | 2.6681 | |
| Dividend Yield | 0.0526 | |
| Dividend Share | 244.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 17.3716 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
06/30 10:50 EST - zacks.com
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.
06/30 07:16 EST - 247wallst.com
Time to Sell the Rally and Buy These 5% and Higher Blue-Chip Dividend Giants
Investors love dividend stocks, especially the blue-chip variety, because they offer a significant income stream and have massive total return potential.
Time to Sell the Rally and Buy These 5% and Higher Blue-Chip Dividend Giants
Investors love dividend stocks, especially the blue-chip variety, because they offer a significant income stream and have massive total return potential.
06/29 09:00 EST - seekingalpha.com
Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)
Bristol-Myers Squibb faces structural headwinds from legacy product losses, but its strong free cash flow and undervalued stock price provide downside protection. The recent $11B partnership with BioNTech signals management's ambition to revitalize growth and address long-term potential in...
Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)
Bristol-Myers Squibb faces structural headwinds from legacy product losses, but its strong free cash flow and undervalued stock price provide downside protection. The recent $11B partnership with BioNTech signals management's ambition to revitalize growth and address long-term potential in...
06/28 08:43 EST - 247wallst.com
5 of the Safest Strong-Buy High-Yield Dividend Stocks Are On Sale Now
Investors love dividend stocks, especially high-yield ones, because they offer a significant income stream and have substantial total return potential.
5 of the Safest Strong-Buy High-Yield Dividend Stocks Are On Sale Now
Investors love dividend stocks, especially high-yield ones, because they offer a significant income stream and have substantial total return potential.
06/26 22:05 EST - businesswire.com
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Abecma--U.S. FDA Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels.
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Abecma--U.S. FDA Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels.
06/26 11:59 EST - 247wallst.com
This Once Dominant Dividend Stock May Be About to Come Back to Life in July
For income investors seeking a timely value stock to buy on the dip, former dividend darling Bristol-Myers Squibb (NYSE:BMY) may fit the bill as one of the top names to watch in the month of July.
This Once Dominant Dividend Stock May Be About to Come Back to Life in July
For income investors seeking a timely value stock to buy on the dip, former dividend darling Bristol-Myers Squibb (NYSE:BMY) may fit the bill as one of the top names to watch in the month of July.
06/25 11:05 EST - zacks.com
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
06/24 10:16 EST - seekingalpha.com
10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” — Barron's Weekly. In Barron's, Steven...
10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” — Barron's Weekly. In Barron's, Steven...
06/24 10:00 EST - zacks.com
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
06/24 09:00 EST - seekingalpha.com
Bargain Alert: I'm Buying Monthly Dividends Up To 7% Yield
Timing of income is an important consideration. Monthly dividend stocks provide recurring income and faster compounding of wealth. I highlight two monthly dividend payers that are undervalued while supporting well-covered yields. Both carry strong balance sheets with A- and BBB+ credit ratings and...
Bargain Alert: I'm Buying Monthly Dividends Up To 7% Yield
Timing of income is an important consideration. Monthly dividend stocks provide recurring income and faster compounding of wealth. I highlight two monthly dividend payers that are undervalued while supporting well-covered yields. Both carry strong balance sheets with A- and BBB+ credit ratings and...
06/24 08:00 EST - seekingalpha.com
2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered dividends. Both carry moat-worthy attributes and provide economically essential products and services...
2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered dividends. Both carry moat-worthy attributes and provide economically essential products and services...
06/20 11:06 EST - zacks.com
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
06/20 09:00 EST - seekingalpha.com
I'm Buying Dividend Giants At Huge Discounts
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth outlook. The market seems to be overly rotated on near-term headwinds while ignoring the long-term...
I'm Buying Dividend Giants At Huge Discounts
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth outlook. The market seems to be overly rotated on near-term headwinds while ignoring the long-term...
06/17 16:16 EST - businesswire.com
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
06/16 18:46 EST - zacks.com
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note
Bristol Myers Squibb (BMY) concluded the recent trading session at $48.66, signifying a -2.19% move from its prior day's close.
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note
Bristol Myers Squibb (BMY) concluded the recent trading session at $48.66, signifying a -2.19% move from its prior day's close.
06/16 06:59 EST - businesswire.com
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #18ICML--BMS Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi.
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #18ICML--BMS Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi.
06/16 04:25 EST - fool.com
2 Beaten-Down Dividend Stocks to Buy Right Now
Stocks experienced significant volatility this year, which can sometimes make it challenging to keep a positive outlook. In times like these, it's worthwhile to remember that stock-market swings, even full-blown crashes, are par for the course; they don't change the fact that over the long run,...
2 Beaten-Down Dividend Stocks to Buy Right Now
Stocks experienced significant volatility this year, which can sometimes make it challenging to keep a positive outlook. In times like these, it's worthwhile to remember that stock-market swings, even full-blown crashes, are par for the course; they don't change the fact that over the long run,...
06/13 10:50 EST - zacks.com
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
06/12 10:16 EST - zacks.com
BMY Reports Positive Data on Sotyktu From Arthritis Study
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
BMY Reports Positive Data on Sotyktu From Arthritis Study
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.